To investigate the impact of the SDF-1α/CXCR4 axis on the stemness traits of GBM, we introduced AMD3100 (plerixafor), a CXCR4 antagonist, to SDF-1α-treated GBM cells. This evidence concerns the gene CXCR4 and glioblastoma.